Bausch Health Companies Inc. SEC filings BHC
Bausch Health Companies Inc. has 1,004 filings in SEC EDGAR's recent list, going back to May 4, 2016. Its latest annual report, Form ARS, was filed on Apr 8, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Oct 29, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Oct 28, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| SD | Specialized disclosure (conflict minerals) | Jun 1, 2026 | — |
| SC TO-T/A | Filing | Sep 11, 2025 | — |
| SC TO-T/A | Filing | Aug 26, 2025 | — |
| SC TO-T | Filing | Aug 12, 2025 | — |
| SC TO-C | Filing | Jul 31, 2025 | — |
| SC TO-C | Filing | Jul 30, 2025 | — |
| SC TO-C | Filing | Jul 29, 2025 | — |
| SC TO-C | Filing | Jul 29, 2025 | — |
| SD | Specialized disclosure (conflict minerals) | May 30, 2025 | — |
| CERT | Nyse certification | Apr 17, 2025 | — |
| 8-A12B | Filing | Apr 15, 2025 | — |
| SD | Specialized disclosure (conflict minerals) | Sep 20, 2024 | — |
| SD | Specialized disclosure (conflict minerals) | Jul 19, 2023 | — |
| SD | Specialized disclosure (conflict minerals) | Jun 2, 2022 | — |
| SD | Specialized disclosure (conflict minerals) | Jun 24, 2021 | — |
| SD | Specialized disclosure (conflict minerals) | Jun 1, 2020 | — |
| UPLOAD | Letter from the SEC | Sep 16, 2019 | — |
| CORRESP | Letter to the SEC | Aug 22, 2019 | — |
| UPLOAD | Letter from the SEC | Aug 8, 2019 | — |
| SD | Specialized disclosure (conflict minerals) | Jun 5, 2019 | — |
| CT ORDER | Filing | Mar 15, 2019 | — |
| SD | Specialized disclosure (conflict minerals) | Jun 8, 2018 | — |
| SD | Specialized disclosure (conflict minerals) | May 31, 2017 | — |
| UPLOAD | Letter from the SEC | Oct 31, 2016 | — |
| CORRESP | Letter to the SEC | Oct 28, 2016 | — |
| UPLOAD | Letter from the SEC | Oct 14, 2016 | — |
| CORRESP | Letter to the SEC | Oct 6, 2016 | — |
| CORRESP | Letter to the SEC | Sep 21, 2016 | — |
| UPLOAD | Letter from the SEC | Sep 8, 2016 | — |
| CORRESP | Letter to the SEC | Aug 10, 2016 | — |
| CORRESP | Letter to the SEC | Jul 26, 2016 | — |
| UPLOAD | Letter from the SEC | Jul 13, 2016 | — |
| SD | Specialized disclosure (conflict minerals) | May 31, 2016 | — |
| NT 10-Q | Filing | May 10, 2016 | Mar 31, 2016 |
Showing 34 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BHC (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- NJ
- Headquarters
- Quebec, Quebec, Canada
- SEC filer status
- Large accelerated filer
- SEC CIK
- 885590
- Former names
- Valeant Pharmaceuticals International, Inc. (until Jul 3, 2018); BIOVAIL Corp (until Sep 27, 2010); BIOVAIL CORP INTERNATIONAL (until Apr 7, 2010); BIOVAIL CORPORATION INTERNATIONAL (until Jan 5, 2001)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.